Erythroblast predominance without CD41/cyCD41-positive blasts predicts favorable prognosis in patients with myelodysplastic syndromes and acute myeloid leukemias treated with azacitidine

Erythroblast predominance without CD41/cyCD41-positive blasts predicts favorable prognosis in patients with myelodysplastic syndromes and acute myeloid leukemias treated with azacitidine

This study examined the prognostic impact of erythroblast predominance (EP) in 61 patients with myelodysplastic syndromes (MDS) ( n  = 51) or acute myeloid leukemia ( n  = 10) treated with azacitidine. Median age was 78 years. EP, defined as > 40% erythroblasts and M/E 

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of hematology 2022-06, Vol.115 (6), p.852-859
Hauptverfasser: Matsuoka, Akihito, Tanibuchi, Masaki, Yamazaki, Ieharu, Taoka, Teruhisa
Format: Artikel
Sprache:eng
Schlagworte:
Acute myeloid leukemia
Disorders
Erythroblasts
Hematology
Karyotypes
Leukemia
Medical prognosis
Medicine
Medicine & Public Health
Multivariate analysis
Myelodysplastic syndrome
Myelodysplastic syndromes
Oncology
Original Article
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This study examined the prognostic impact of erythroblast predominance (EP) in 61 patients with myelodysplastic syndromes (MDS) ( n  = 51) or acute myeloid leukemia ( n  = 10) treated with azacitidine. Median age was 78 years. EP, defined as > 40% erythroblasts and M/E 
ISSN:0925-5710
1865-3774
DOI:10.1007/s12185-022-03317-9